SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, TGI, AVAV, NARI on Behalf of ShareholdersNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCRN, NARI, VTS, QTRX on Behalf of ShareholdersNEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NARI, QTRX, CTV on Behalf of ShareholdersNEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HEES, NARI, SSTK on Behalf of ShareholdersNEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: H&E Equipment Services, Inc. (Nasdaq - HEES), Inari Medical, Inc. (Nasdaq - NARI), Paycor HCM, Inc. (Nasdaq - PYCR), Shutterstock, Inc. (NYSE - SSTK)BALA CYNWYD, Pa., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LBRDA, NARI, ML, POAI on Behalf of ShareholdersNEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates NEUE, VCSA, SSTK, NARI on Behalf of ShareholdersNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of ShareholdersNEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (
NYSESYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NARI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inari Medical, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inari Medical, Inc. (
NASDAQNARI) to Stryker for $80.00 per share in cash is fair to Inari shareholders.
Inari Medical to Present at the J.P. Morgan Healthcare ConferenceIRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that its management team is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 a.m. Pacific Time.
Inari Medical Announces Joint Venture in Greater ChinaIRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced it has entered into a joint venture with 6 Dimensions Capital (“6 Dimensions”) and its successor fund 120 Capital, and VFLO Medical (“VFLO”), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari’s innovative technology for patients with significant unmet needs in Greater China.
Inari Medical to Participate in the Jefferies London Healthcare ConferenceIRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 10:00 AM Greenwich Mean Time / 5:00 AM Eastern Time.
Inari Medical Reports Third Quarter 2024 Financial ResultsIRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024.
Inari Medical Announces Partnership with AVF and NBCA on DEFIANCE TrialIRVINE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- In recognition of World Thrombosis Day, Inari Medical, Inc. (
NASDAQNARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced collaborative partnerships with the American Venous Forum (“AVF”) and the National Blood Clot Alliance (“NBCA”) on the DEFIANCE trial. This prospective, multinational, randomized controlled trial (“RCT”) will evaluate and compare clinical outcomes in patients with deep vein thrombosis (“DVT”) treated with Inari's ClotTriever System versus anticoagulation alone.
Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT PresentationIRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.
Inari Medical to Announce Third Quarter 2024 Financial ResultsIRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.
Inari Medical to Present at Upcoming Investor ConferencesIRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:
Inari Medical Announces Chief Financial Officer Retirement and Succession PlanMitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024
Inari Medical Reports Second Quarter 2024 Financial ResultsIRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its second quarter ended June 30, 2024.
Inari Medical to Announce Second Quarter 2024 Financial ResultsIRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (
NASDAQNARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
